ArticleGeburtshilfe und Frauenheilkunde2014
Molecular Markers as Prognostic Factors in DCIS and Small Invasive Breast Cancers.
Article in Geburtshilfe und Frauenheilkunde, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 15 citations in OpenAlex.
- How much do we know about the metastatic process?Clinical & experimental metastasis · 2024Review
- Immune cell infiltrate in ductal carcinoma in situ and the risk of dying from breast cancer: case-control study.The British journal of surgery · 2024Article
- Article
- Human Ductal Carcinoma In Situ: Advances and Future Perspectives.Cold Spring Harbor perspectives in medicine · 2023Review
- Multiple Metastases of the Liver and Lung After Breast-Conserving Surgery for Ductal CarcinomaFrontiers in oncology · 2022Review
- Novel role for the Golgi membrane protein TMEM165 in control of migration and invasion for breast carcinoma.Oncotarget · 2020Article
- Legumain is an independent predictor for invasive recurrence in breast ductal carcinoma in situ.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2019Article
- Is invasion a necessary step for metastases in breast cancer?Breast cancer research and treatment · 2018Review
- Clinicopathological implications of Tiam1 overexpression in invasive ductal carcinoma of the breast.BMC cancer · 2016Article
- miR-3646 promotes cell proliferation, migration, and invasion via regulating G2/M transition in human breast cancer cells.American journal of translational research · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ductal carcinoma in situ (DCIS) accounts for up to half of screen-detected breast cancers and thus constitutes a major public health problem. Despite effective current treatment many patients with DCIS are either over- or undertreated because of the paucity of precise models to predict recurrence or progression. The combination of clinical and molecular factors as already applied for invasive disease may help to build such models also for DCIS. We compared 53 DCIS (36.6 %) and 92 (63.4 %) invasive breast cancer cases and found no significant differences in age, receptor status of ER, PR, and HER2, and the use of radiotherapy. Interestingly, the proportion of disseminated tumor cells (DTC) did also not significantly differ between DCIS and invasive cases (p = 0.57). A negative PR status was associated with the detection of DTCs (p = 0.026). We then compared relationships of clinical parameters and biomarkers with patients' prognosis in 43 DCIS and 40 small invasive tumors ≤ 5 mm (T1a). ER negativity was associated with shorter relapse free survival in the complete cohort (p = 0.004) and showed a trend in both subgroups (p = 0.053 for DCIS and p = 0.046 for T1a, respectively). In conclusion, we found markedly similar properties of both DCIS and small invasive breast cancers with respect to the distribution of several parameters as well as to the prognostic value of biomarkers. DCIS with a luminal phenotype seem to be characterized by a favourable prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.